Boehringer Ingelheim’s nintedanib has been designated a Promising Innovative Medicine for the treatment of malignant pleural mesothelioma (MPM) by the UK Medicine and Healthcare Products Regulatory Agency.
Original Article: PIM status for Boehringer’s mesothelioma drug
NEXT ARTICLE